Lycia Therapeutics Upsizes IPO to 17.64M Shares, Prices at $18 Top of Range
Tom Rudovsky · Reported by Reuters
More coverage: Healthcare
Sentiment
Positive
Importance
7
Price
--
Mkt Cap
--
52W Low
--
52W High
--
52W Position
Off High
Rel. Volume
Market data snapshot near publication time
Summary
Lycia Therapeutics priced its Nasdaq IPO at $18.00 a share, the top of the $16-$18 range it set two days ago, and upsized the deal to 17,640,000 shares from 14.7 million. The larger size and top-of-range pricing point to solid demand for the offering. At $18.00, the 17.64 million shares raise roughly $317.5 million gross, well above the roughly $227.8 million net at the midpoint on the original terms. This is the final step before LYCA begins trading, so the first session's open versus the $18.00 print is the number that matters now.
This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.
Price Chart
LYCA - Latest Insights
LYCA
Oct 20, 2026, 3:33 PM EDT